About Fresenius SE & Co. KGaA

Fresenius AG, a global health care company, provides products and services for dialysis, hospital, and medical care of patients at home. In addition, the company focuses on hospital management, as well as on engineering and services for hospitals and the pharmaceutical industry. The company operates in three segments: Fresenius Medical Care, Fresenius Kabi, and Fresenius ProServe. Fresenius Medical Care Fresenius Medical Care AG serves as an integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. Through its network of approximately 1,630 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides Dialysis Treatment to approximately 125,900 patients around the globe. Fresenius Medical Care also provides Dialysis Products, such as hemodialysis machines, dialyzers and related disposable products. On May 4, 2005, Fresenius Medical Care AG announced that it has entered into an agreement to acquire Renal Care Group, Inc., a dialysis service provider. The DiaSafe filter, the On-line Clearance Monitor, which is used to monitor the vascular access and the Twister also developed. DiaSafe is used to produce ultrapure dialysis fluid during hemodialysis and minimizes the risk of infection through dialysis. Twister offers blood flow monitoring during treatment. Haemodialysis: The company offers machines for haemodialysis, haemodiafiltration, haemofiltration, acute dialysis, plasmafiltration; Low-Flux dialysers (Fresenius Polysulfon); High-Flux dialysers (Fresenius Polysulfon); FX-class dialysers (Helixone); Haemofilters for acute and chronic renal replacement therapy; Plasmafilters; Dialysis fluid filters; Tubing systems; Dialysis cannulae; Dialysis fluids; Dialysis concentrates (liquid, dry); Haemofiltration solutions; Irrigation solutions; Disinfectants; Water treatment systems; Analysis devices; and Data management systems. Peritoneal dialysis: The company offers machines and tubing systems for Automated Peritoneal Dialysis (APD); Peritoneal dialysis solutions; CAPD systems; CAPD double chamber systems; Peritoneal dialysis catheters; and Accessories. Dialysis care: The company offers Dialysis clinics for chronic haemodialysis treatment; Acute in-patient dialysis treatment; and Training (haemodialysis and peritoneal dialysis). Spectra Renal Management: The company offers Laboratory and diagnostic dialysis-related services; Data management; and Managed care services for dialysis patients. Adsober technology: The company offers LDL apheresis: DALI system; and Immunoadsorption: Prosorba system and Immunosorba system. Fresenius Kabi Fresenius Kabi engages in Infusion Therapy and Clinical Nutrition in Europe and in its major countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions for fluid substitution, blood volume replacement, intravenously administered drugs, as well as parenteral and enteral nutrition. Furthermore, the company offers medical devices for the application of Infusion Therapy and Clinical Nutrition and Infusion Management. In addition, Fresenius Kabi is active in the field of Transfusion Technology, supplying blood processing systems, as well as blood bags and filters. Fresenius Kabi’s portfolio comprises three business units that include: Infusion therapy: Products for fluid and blood-volume replacement, as well as intravenously administered drugs, such as anesthetics for general anesthesia, as well as medical devices for the administration of infusion therapies and for infusion management. The company offers basic solutions; solutions for osmotic therapy; irrigation solutions/urology; infusion solutions for blood volume replacement and haemodilution therapy; I.V. anaesthetics; I.V. anti-infective drugs and disinfectants; I.V. catecholamines; and I.V. packaging systems. Clinical Nutrition: Parenteral (intravenous) and enteral (via sip and tube feeds) nutrition for patients who are unable to not allowed to eat any or sufficient normal food, as well as medical devices for the administration of nutrition therapies. The company offers application technology; technical equipment for irrigation systems; suprapubic drainage systems; infusion devices and accessories; in-dwelling venous cannulae; central venous catheters; wound drainage systems; implantable port systems; and portable drug pumps. In nutrition therapy, the company offers parenteral nutrition; Industrial All-In-One mixtures (3 and 2 chamber bags, All-In-One bags); Standard and special amino acid solutions; lipid emulsions; products for immunonutrition; Additives; devices and support tools for parenteral nutrition and application; scientific support and information; and training and education. Transfusion technology: A range of products for blood banks and blood-donations organizations for the production of blood products. Transfusion technology offers blood bags; blood bag systems with in-line filters; leukocyte filters; transfer bags; platelet storage bags; mixing devices; cooling and transportation systems; automatic blood component processing systems; sealing devices; sterile docking devices; blood cell separators for haemapheresis, therapeutic apheresis, multi-component donation; stem cell bags; cryopreservation bags; autotransfusion; processing solutions; and donor couches. In Ambulatory care, the company offers concepts for management and provision of ambulatory therapies for antiviral, antimyotic, antibiotic and cytostatic infusion therapies; enteral and parenteral nutrition therapies; respiratory therapies; wound care; incontinence care; diabetes monitoring; patient monitoring; and technical service. In Infusion technology, the company offers Infusion and clinical fluid data management systems; Syringe pumps; I.V. anaesthesia and analgesia systems; volumetric infusion pumps; enteral feeding systems; disposables and accessories; clinical medical disposables for infusion and wound drainage; patient data management system ‘PDMS’. Customers: Fresenius Kabi’s products are used in hospitals, as well as in out-patient medical care. Fresenius ProServe Fresenius ProServe offers services for international health care systems. The Portfolio includes hospital management, as well as engineering and services for hospital and the pharmaceutical industry. It focuses on three business areas, hospital management in Germany through its subsidiary, Wittgensteiner Kliniken; hospital engineering and services; and engineering and services for the pharmaceutical industry. As of December 31, 2004, the company operated and managed 13 acute and 19 post acute hospitals in Germany and the Czech Republic with a total of around 6,100 beds. VAMED: The company offers worldwide projects and services for health facilities; feasibility studies; operational and organizational planning; IT systems planning; architectural planning; planning of medical-technical equipment and packages; medical-technical maintenance; buildings technology planning; facility management; project developement and management; turn-key projects; financial engineering; and general and technical management of health facilities. hospitalia international: The company offers feasibility studies; consultancy; project development, management and control; design; turn-key projects; medical and technical equipment for hospitals; installation; staff training; and maintenance services. Pharmaplan: The company offers engineering and plant design for the pharmaceuticals and medical device industry; feasibility studies; consulting and engineering; turn-key projects; validation and management; logistics and warehousing; services for pharmaceutical production; training; facility management for pharmaceutical companies; supply, installation and maintenance of water systems/preparation systems for the Pharma industry. Fresenius Biotech In addition, the group, through Fresenius Biotech, focuses on the development and marketing of biopharmaceuticals in the fields of oncology, immunology, and regenerative medicine. Fresenius Biotech develops therapies with trifunctional antibodies for the treatment of cancer, as well as cell therapies for the treatment of the immune system. In the field of polyclonal antibodies, Frensenius Biotech has marketed ATG-Fresenius S.ATG-Fresenius S is an immunosuppressive agent used to suppress graft rejection following an organ transplantation. Market Fresenius operates in Europe, Asia, North America, Asia Pacific, Latin America, and Africa. History Fresenius AG was founded in 1912.